Rifampicin & Isoniazid Tablets

Product Composition & Strength (RH 300/150)

We supply this product in standardized Fixed-Dose Combinations (FDCs) as per international pharmacopoeial standards.

Active Ingredient	Strength (per Tablet)	Primary Clinical Function
Rifampicin IP/BP/USP	300 mg	The RNA Blocker: Sterilizing agent against TB bacilli.
Isoniazid IP/BP/USP	150 mg	The Wall Breaker: Potent bactericidal agent.
Excipients	Pharma Grade	The Matrix: Ensures stability of the FDC.

Rifampicin & Isoniazid Tablets

Rifampicin & Isoniazid Tablets (300 mg / 150 mg)

Healthy Inc is a specialized global supplier and exporter of advanced infectious disease, pulmonary, and public health therapeutics. We provide ultra-high-purity, kinetically stable Rifampicin and Isoniazid FDC Tablets, manufactured in WHO–GMP certified, high-precision anti-tubercular manufacturing facilities. This "First-Line Antitubercular Combination" is a massive-volume strategic export to National TB Programs, government health ministries, and international B2B distributors, serving as the globally preferred intervention for the effective treatment of Mycobacterium tuberculosis.

Product Overview

This formulation operates as a "Multiphase Bactericidal System." It ensures patient safety by ensuring high adherence through fixed-dose combinations, which physically reduces the risk of developing drug-resistant strains.

• Mechanism 1 (Transcription Inhibition - Rifampicin): Rifampicin physically binds to the beta-subunit of bacterial DNA-dependent RNA polymerase. This chemically blocks the initiation of RNA synthesis, physically stopping the bacteria from producing proteins and replicating.

• Mechanism 2 (Cell Wall Synthesis Inhibition - Isoniazid): Isoniazid is a pro-drug that chemically targets the InhA enzyme. This physically inhibits the synthesis of Mycolic Acids, the essential chemical components of the mycobacterial cell wall, causing the bacteria to lose physical integrity and die.

• Mechanism 3 (Fixed-Dose Synergy): By combining both agents, the treatment physically targets both rapidly dividing and semi-dormant bacteria, chemically ensuring a more comprehensive "kill rate" than monotherapy.

Product Composition & Strength (RH 300/150)

We supply this product in standardized Fixed-Dose Combinations (FDCs) as per international pharmacopoeial standards.

Active Ingredient	Strength (per Tablet)	Primary Clinical Function
Rifampicin IP/BP/USP	300 mg	The RNA Blocker: Sterilizing agent against TB bacilli.
Isoniazid IP/BP/USP	150 mg	The Wall Breaker: Potent bactericidal agent.
Excipients	Pharma Grade	The Matrix: Ensures stability of the FDC.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on infectious diseases / Others)

• CAS Numbers: 13292-46-1 (Rifampicin) / 54-85-3 (Isoniazid)

• Dosage Form: Oral Tablet (Film-Coated)

• Packaging: 10 or 28 Tablets per Blister in high-barrier Alu-Alu (to protect Rifampicin from moisture and light). Our specialized packaging ensures 36-month stability in Zone IVb tropical climates.

Manufacturing Authority & Compliance

• FDC Stability Management: Rifampicin and Isoniazid are physically sensitive to interaction in the presence of moisture. Our manufacturing process utilizes Advanced Dry-Granulation and Moisture-Barrier Coating, physically ensuring the two agents do not chemically degrade each other—a critical commercial factor for TB shelf-life.

• Light-Protected Processing: Rifampicin is physically light-sensitive. We utilize Opaque Film Coating and amber-tinted or Alu-Alu blister foils, chemically ensuring the potency remains 100% until the point of consumption.

• Bioavailability Validation: We utilize Comparative Dissolution Profiling, physically ensuring the FDC releases both drugs at the correct rate for synchronized chemical absorption in the digestive tract.

Primary Indications

• Pulmonary Tuberculosis: Continuation phase treatment of active TB.

• Extra-Pulmonary Tuberculosis: Management of TB in the lymph nodes, bones, or meninges.

• Latent TB Infection (LTBI): Preventive therapy in high-risk populations (as per local clinical guidelines).

Usage Instructions

• Administration: Swallow the tablet physically whole with a glass of water.

• Timing: It is physically critical to take this medication on an empty stomach (1 hour before or 2 hours after meals). Food physically reduces the chemical absorption of both Rifampicin and Isoniazid.

• Consistency: Adherence is physically vital. Missing doses chemically increases the risk of Multi-Drug Resistant TB (MDR-TB).

• Biological Effect Note: Patients should be physically informed that Rifampicin will chemically turn urine, sweat, and tears an orange-red color; this is physically harmless.

Safety Warning: For Professional Use Only. Hepatic Note: Both agents can physically cause Hepatotoxicity (liver damage); monitor liver enzymes chemically throughout treatment. Peripheral Neuropathy: Isoniazid may physically cause numbness; often chemically co-prescribed with Pyridoxine (Vitamin B6). Contraindication: Do not use in patients with acute liver disease, jaundice, or known hypersensitivity to Rifamycins or Isoniazid.

Global Export & Contract Manufacturing

Healthy Inc is a premier Anti-Tubercular and Public Health Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for high-volume TB FDCs. Whether you are a National Ministry of Health in Africa or a B2B Pharma Marketplace partner in the CIS or SE Asia, we ensure secure, WHO-GMP compliant delivery.

Commercial Inquiries:

WhatsApp/Call: +91 7710003340

Email: info@healthyinc.co.in